Drug Development Considerations for Additives to Organ Preservation Solutions

Area of Science:

• Pharmacology and Drug Development
• Transplantation Medicine
• Regulatory Science

Background:

• Novel therapeutic agents in organ preservation solutions offer potential benefits for transplant recipients.
• Unclear development expectations and limited regulatory guidance hinder the advancement of these agents.
• Existing strategies for parenteral drugs provide a foundation, but require adaptation for organ preservation applications.

Purpose of the Study:

• To articulate a drug development strategy for novel therapeutic agents in organ preservation solutions.
• To address the unmet needs and enhance outcomes in organ transplantation.
• To provide considerations for justified deviations from standard parenteral drug development.

Main Methods:

• Leveraging development expectations for parenteral drug products (e.g., intravenous administration).
• Comparing the proposed strategy with existing US Food and Drug Administration (FDA) regulatory guidance.
• Drawing upon internal program experience from Genentech for kidney transplantation.

Main Results:

• A comprehensive drug development strategy tailored for organ preservation solutions has been proposed.
• Potential areas for clarification in regulatory guidance have been identified.
• The strategy considers adaptations for unique aspects of organ preservation compared to conventional parenteral routes.

Conclusions:

• A defined strategy can guide the development of novel therapeutic agents for organ preservation.
• Addressing regulatory ambiguities is crucial for advancing transplantation medicine.
• This framework, based on internal experience, can facilitate future development programs.